| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Atyr Pharma Inc (ATYR) has 4 insiders with recent SEC Form 4 filings, including 9 buys and 9 sells. ATYR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.50M | $1.42M | - | |
| Dir | 1.41M | $1.34M | - | |
| CFO | 412.5K | $390.3K | - | |
| Other | 412.5K | $390.3K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2018 | Schimmel Paul53 | Director | Buy | 42,749 | $0.74 | $31,461.07 | +3.0% | |
| Aug 30, 2018 | Schimmel Paul53 | Director | Buy | 164,411 | $0.74 | $121,573.38 | +14.5% | |
| May 18, 2018 | Schimmel Paul53 | Director | Buy | 150,000 | $1.00 | $149,445.00 | +39.7% | |
| May 16, 2018 | Ecor1 Capital Fund Qualified, L.P. | 10% Owner | Sell | 3,209,316 | $0.93 | $2,999,055.65 | -36.5% | |
| Feb 8, 2018 | Blake John T | Senior Vice President, Finance | Sale+OE | 1,402 | $3.40 | $4,766.80 | -42.1% | |
| Feb 8, 2018 | Amanullah Ashraf | See Remarks | Sale+OE | 1,402 | $3.40 | $4,766.80 | -42.1% | |
| Nov 13, 2017 | Ecor1 Capital Fund Qualified, L.P. | 10% Owner | Sell | 13,832 | $4.08 | $56,474.72 | -0.1% | |
| Nov 1, 2017 | Ecor1 Capital Fund Qualified, L.P. | 10% Owner | Buy | 29,607 | $4.84 | $143,333.35 | +0.5% | |
| Aug 31, 2017 | Schimmel Paul53 | Director | Buy | 94,336 | $2.65 | $249,990.40 | +33.3% | |
| Aug 31, 2017 | Mendlein John50 | CEO And Director | Buy | 37,736 | $2.65 | $100,000.40 | +11.4% |